---
schema_version: "secwatch.filing_event.v1"
accession: "0001658247-26-000052"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2026-08-03T20:09:02+00:00"
generated_at: "2026-08-03T20:10:07.498662+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Vertex to acquire Crinetics for $85/share (~$10B equity value); Q2 PALSONIFY revenue $24M

## Summary
- Vertex to acquire Crinetics for $85.00 per share cash, total equity value ~$10.0B (~$8.8B net of cash).
- Transaction approved by both boards, expected to close Q3 2026 subject to regulatory and stockholder approvals.
- Q2 2026 net product revenue from PALSONIFY $24.0M, up from $10.3M in Q1 2026.
- Net loss $120.9M for Q2 2026 vs $115.6M in Q2 2025.
- Cash and investments $1.2B as of June 30, 2026.

## SEC filing metadata
- accession: 0001658247-26-000052
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2026-08-03T20:09:02+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000165824726000052/0001658247-26-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000165824726000052/crnx-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001658247-26-000052
- JSON: https://secwatch.observer/filing/0001658247-26-000052.json
- Plain text: https://secwatch.observer/filing/0001658247-26-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.